1,139 Shares in Insulet Co. (NASDAQ:PODD) Purchased by Counterpoint Mutual Funds LLC

Counterpoint Mutual Funds LLC bought a new position in shares of Insulet Co. (NASDAQ:PODD) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 1,139 shares of the medical instruments supplier’s stock, valued at approximately $297,000.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Integrated Wealth Concepts LLC raised its stake in Insulet by 1.7% in the 3rd quarter. Integrated Wealth Concepts LLC now owns 2,561 shares of the medical instruments supplier’s stock worth $596,000 after purchasing an additional 42 shares in the last quarter. Nisa Investment Advisors LLC raised its stake in Insulet by 1.0% in the 4th quarter. Nisa Investment Advisors LLC now owns 4,388 shares of the medical instruments supplier’s stock worth $1,146,000 after purchasing an additional 43 shares in the last quarter. Glenmede Trust Co. NA raised its stake in Insulet by 2.3% in the 3rd quarter. Glenmede Trust Co. NA now owns 2,080 shares of the medical instruments supplier’s stock worth $484,000 after purchasing an additional 47 shares in the last quarter. Graypoint LLC raised its stake in Insulet by 5.3% in the 4th quarter. Graypoint LLC now owns 930 shares of the medical instruments supplier’s stock worth $243,000 after purchasing an additional 47 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB raised its stake in Insulet by 9.6% in the 4th quarter. Wilmington Savings Fund Society FSB now owns 538 shares of the medical instruments supplier’s stock worth $140,000 after purchasing an additional 47 shares in the last quarter.

Insulet Trading Down 0.4 %

PODD opened at $260.47 on Wednesday. Insulet Co. has a fifty-two week low of $160.19 and a fifty-two week high of $289.46. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The firm has a market capitalization of $18.29 billion, a price-to-earnings ratio of 44.99, a PEG ratio of 3.62 and a beta of 1.29. The company’s 50 day moving average price is $272.30 and its two-hundred day moving average price is $256.12.

Insulet (NASDAQ:PODD) last posted its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.00 by $0.15. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The firm had revenue of $597.50 million for the quarter, compared to analyst estimates of $582.02 million. As a group, research analysts predict that Insulet Co. will post 3.92 earnings per share for the current year.

Insiders Place Their Bets

In other news, EVP Eric Benjamin sold 12,394 shares of the company’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total value of $3,470,320.00. Following the sale, the executive vice president now directly owns 11,383 shares of the company’s stock, valued at approximately $3,187,240. This represents a 52.13 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 0.47% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on PODD shares. Citigroup lifted their price objective on shares of Insulet from $310.00 to $355.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. TD Cowen boosted their target price on shares of Insulet from $264.00 to $324.00 and gave the company a “buy” rating in a research report on Friday, January 3rd. Canaccord Genuity Group boosted their target price on shares of Insulet from $304.00 to $324.00 and gave the company a “buy” rating in a research report on Friday, February 21st. Raymond James restated an “outperform” rating and issued a $328.00 target price (up from $294.00) on shares of Insulet in a research report on Friday, February 21st. Finally, Wells Fargo & Company boosted their target price on shares of Insulet from $305.00 to $322.00 and gave the company an “overweight” rating in a research report on Friday, February 21st. Four investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $292.06.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.